Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: A dose-response study

Journal of the American College of Cardiology

Volumn 28, Issue 1, 1996, Pages 130-136

  Ellenbogen, Kenneth A ^a,g   Stambler, Bruce S ^a   Wood, Mark A ^a   Sager, Philip T ^b   Wesley Jr , Robert C ^c   Meissner, Marc D ^d   Zoble, Robert G ^e   Wakefield, Linda K ^f   Perry, Kimberly T ^f   Vanderlugt, James T ^f  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

^e UNIVERSITY OF FLORIDA HEALTH JACKSONVILLE   (United States)

^f PFIZER INC   (United States)

^g VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; IBUTILIDE FUMARATE; PLACEBO;

ADULT; AGED; ARTICLE; CARDIOVERSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART EJECTION FRACTION; HEART VENTRICLE TACHYCARDIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SINUS RHYTHM; TREATMENT OUTCOME;

EID: 9444256916     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/0735-1097(96)00121-0     Document Type: Article

References (21)

1. 1. Buchanan LV, Turcotte UM, Kabell GG, Gibson JK. Antiarrhythmic and electrophysiologic effects of ibutilide in a chronic canine model of atrial flutter. J Cardiovasc Pharmacol 1993;33:10-4.
2. 2. Buchanan LV, Kabell G, Brunden MN, Gibson JK. Comparative assessment of ibutilide, D-sotalol, clofilium, E-4031, and UK-68,798 in a rabbit model of proarrhythmia. J Cardiovasc Pharmacol 1993;22:540-9.
3. 3. Nabih MA, Prcevski P, Fromm BS, et al. Effect of ibutilide, a new class III agent, on sustained atrial fibrillation in a canine model of acute ischemia and myocardial dysfunction induced by microembolization. PACE 1993;16:1975-83.
4. 4. Cimini MG, Branden MN, Gibson JK. Effects of ibutilide fumarate, a novel antiarrhythmic agent, and its enantiomers on isolated rabbit myocardium. Eur J Pharmacol 1992;222:93-8.
5. 5. Lee KS. Ibutilide, a new compound with potent class III antiarrhythmic activity, activates a slow inward Na current in guinea pig ventricular cells. J Pharmacol Exp Ther 1992;262:99-108.
6. 6. Yang T, Snyders DJ, Roden DM. Ibutilide, a methanesulfonamilide antiarrhythmic, is a potent blocker of the rapidly-activating delayed rectifier K+ current (Ikr) in AT-1 cells: concentration, time-, voltage-and use-dependent effects. Circulation 1995;91:1799-806.
7. 7. Lee KS, Tsai TD, Lee EW. Membrane activity of class III antiarrhythmic compounds; a comparison between ibutilide, d-sotalol, E-4031, sematilide and dofetilide. Eur J Pharmacol 1994;234:43-53.
8. 8. Fenster PE, Comess KA, Marsh R, Katzenber C, Hager WD. Conversion of atrial fibrillation to sinus rhythm by acute intravenous procainamide infusion. Am Heart J 1983;106:501-4.
9. 9. Halpern SW, Ellrodt G, Singh BN, Mandel WJ. Efficacy of intravenous procainamide infusion on converting atrial fibrillation to sinus rhythm. Br Heart J 1980;44:589-95.
10. 10. Madrid AH, Moro C, Marin-Huerta E, Mestre JL, Novo L, Costa A. Comparison of flecainide and procainamide in cardioversion of atrial fibrillation. Eur Heart J 1993;14:1127-31.
11. 11. Fujiki A, Yoshida S, Tani M, Inoue H. Efficacy of Class Ia antiarrhythmic drugs in converting atrial fibrillation unassociated with organic heart disease and their relation to atrial electrophysiologic characteristics. Am J Cardiol 1994;74:282-3.
12. 12. Crijns HJG, Van Wijk LM, Van Gilst WH, Kingma JH, Van Gelder K, Lie K. Acute conversion of atrial fibrillation in sinus rhythm: clinical efficacy of flecainide acetate. Comparison of two regimens. Eur Heart J 1988;9:634-8.
13. 13. Goy JJ, Kaufmann U, Kappenberger L, Sigwart U. Restoration of sinus rhythm with flecainide in patients with atrial fibrillation. Am J Cardiol 1988;62:38D-40D.
14. 14. Borgeat A, Goy J-J, Maendly R, Kaufmann U, Grbic M, Sigwart U. Flecainide versus quinidine for conversion of atrial fibrillation to sinus rhythm. Am J Cardiol 1986;58:496-8.
15. 15. Stambler BS, Wood MA, Belz MK, Sperry RE, VanderLugt JT, Ellenbogen KA. Electrophysiologic determinants of pharmacologic conversion of human atrial fibrillation and flutter: enhanced efficacy of ibutilide, a new class III antiarrhythmic drug [abstract]. Circulation 1993;88(Pt 2):I-445.
16. 16. Volgman AS, Stambler BS, Kappagoda C, et al. Comparison of intravenous ibutilide versus procainamide for the rapid termination of atrial fibrillation or flutter [abstract]. PACE 1996;19(Pt II):608.
17. 17. Bianconi L, Dinelli M, Pappalardo A, et al. Comparison of intravenously-administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicenter, randomized, double-blind, placebo-controlled study. Circulation 1995;92 Suppl I:I-774.
18. 18. Stambler BS, Portnow AS, Wood MA, et al. Proven efficacy of repeated dose intravenous ibutilide, a class III antiarrhythmic drug, for rapid termination of chronic atrial flutter or fibrillation: results of a multicenter placebo-controlled study. J Am Coll Cardiol 1995;25:230A.
19. 19. Daoud EG, Niebauer MJ, Man KC, Strickberger SA, Kou W, Morady F. Prospective assessment of quinidine-induced QT prolongation and proarrhythmia in hospitalized patients. J Am Coll Cardiol 1995;25:220A.
20. 20. Halinen MO, Huttunen M, Paakkinen S, Tarssanen L. Comparison of sotalol with digoxin-quinidine for conversion of acute atrial fibrillation to sinus rhythm. (The sotalol-digoxin-quinidine trial). Am J Cardiol 1995;76:495-8.
21. 21. Hohnloser SH, Van De Loo A, Baedeker F. Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine. J Am Coll Cardiol 1995;26:852-8.